Hypersensitivity Reactions
5
1
2
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
5 treatments under study, led by Silk Fibroin Sylke
Research Leaders
6 sponsors active, led by National Institute of Allergy and Infectious Diseases (NIAID)
Related Conditions
Often studied with 4 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
20%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions
Post-market Safety Study of LUMISIGHT
Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity
Evaluation of Hypersensitivity Reactions to Silk Fibroin Versus 2-octyl Cyanoacrylate Mesh in Shoulder Surgery
Characteristics of Patients With Hypersensitivity Reactions to Intravenous Iron Infusions
Research Network
Common Treatments
- Silk Fibroin Sylke1
- Collection Of Patient Data1
- 2octyl Cyanoacrylate Mesh Dermabond Prineo1
- Vancomycin1
- Dexamethasone1
Active Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)1
- The University of Texas Health Science Center, Houston1
- Loma Linda University1
- Johns Hopkins University1
- University Hospital, Basel, Switzerland1
Top Investigators
The University of Texas Health Science Center, Houston
Loma Linda University Cancer Center
Johns Hopkins University
Lumicell, Inc.
Allergology, University Hospital Basel
Related Conditions
- Vancomycin1
- Healthy Volunteer1
- Allergic Contact Dermatitis1
- Irondeficiency1